Sulfiscon is a Start up developing small molecule allosteric modulators that regulate cellular hydrogen sulfide (H2S) production in order to alleviate disorders of pathologic calcification and inflammation. The start up grew from research started in the Laboratory of Rheumatology Research, CHUV, Lausanne and was created in 2017.

Development of candidate lead compounds to be used to treat pathologic calcification disorders. We employ both in vitro and in vivo tests and have considerable experience in measuring H2S production in vitro and vivo.